Table 4.
HBV and HCV molecular diagnosis | Application | Method | Advantages | Disadvantages | Ref. |
HBV DNA qualitative methods | Diagnose infection | PCR | Low cost; high sensitivity | It only determines the presence or absence of HBV DNA | [81,82,85] |
HBV occult cases identification | |||||
Screening on blood donors | |||||
HBV DNA quantitative methods | Evaluate the prognosis and risk of progression | bDNA | Wide dynamic range | Low sensitivity to detect low HBV DNA levels | [81,82] |
Define the beginning of antiviral treatment | |||||
Monitor antiviral treatment | |||||
Hybrid capture | More sensitive than bDNA; less labor-intensive | Low sensitivity to detect low HBV DNA levels; individual probes are required | [83] | ||
Real time PCR | Capacity of detecting low viral loads; broad dynamic range; do not carry over contamination; can be fully automated | High cost | [85,91] | ||
HBV DNA genotyping methods | Determination of HBV genotype | RFLP | Easily done; low cost; simple, rapid and suitable for large number of samples | Low sensitivity for typing samples with low HBV DNA levels; poor accurate to determine some genotypes | [85,104] |
Genotype specific PCR assays | Automated systems; high sensitivity; easy to perform; suitable for detecting mixed genotype infections | High cost | [107] | ||
Sequence analysis | Identification of patients infected with recombinant genotypes | Technically demanded; time consuming | [107] | ||
HBV DNA aminoacid substitution identification | Identify antiviral resistance to treatment | Direct DNA sequencing | Accurate | Technically demanded; time consuming; necessity of cloning for identification of mixed population | [107,110,111] |
Commercial methods | Sequencing of mixed population, relative quantification of individual mutations with extremely high coverage | Differences between the statistical and biological/clinical relevance of HBV mutation maximal sequence read length and PCR amplification bias | [114] | ||
HCV RNA qualitative methods | To confirm chronic hepatitis C in patients with positive HCV antibodies | RT-PCR | High sensitivity | It only determines the presence or absence of HCV RNA | [121,168] |
To identify virological response during, at the end or after antiviral therapy | Equal sensitivity for all genotypes | ||||
To screen blood donations for evidence of infection with HCV | |||||
Transcription-mediated amplification | High sensitivity; amplifies viral RNA; more sensitivity for detection of genotype 1 | It only determines the presence or absence of HCV RNA | [121,168] | ||
HCV RNA quantitative methods | To guide treatment decisions; To evaluate the prognosis; To monitor the antiviral efficacy of treatment | bDNA | Wide range of detection of HCV independent of HCV genotype (615 IU/mL to 8 million IU/mL) | Low sensitivity to detect samples presenting low HCV RNA levels | [172] |
qRT-PCR | Capacity of detecting low viral loads; broad dynamic range; not carry over contamination; can be fully automated | High cost | [170-173] | ||
HCV RNA genotyping methods | HCV genotyping is mandatory for double antiviral treatment (interferon and ribavirin), since patients infected with genotypes 1 or 4 are treated for longer times than patients infected by genotypes 2 and 3 | RFLP | Easily done; low cost; simple, rapid and suitable for large number of samples | Low sensitivity for typing samples with low HCV RNA levels; Poor accurate to determine some genotypes | [186,187] |
Probes | Easily done; low cost; useful to detect HCV genotypes and subtypes based on region 5’UTR and core and has a low limit of detection | Identify only subtypes 1a and 1b; discrepant results among subtypes when compared to sequence analysis of NS5B region | [180-184] | ||
qPCR | Can be fully automated avoiding contamination; determines the viral genotype and subtypes 1a, 1b, 2a, 2b, 3, 4, 5 and 6 | High cost | [186,187] | ||
Direct sequencing | Gold standard; identification of patients infected with recombinant genotypes | Technically demanded; time consuming | [120,182] | ||
HCV RNA aminoacid substitution identification | Identify antiviral resistance to treatment | Direct Sequencing | Identification of antiviral resistance in majority population | Technically demanded; time consuming; necessity of cloning for identification of quasispecies | [188,189,193] |
Deep Sequencing | Identification on resistant variants predominate in the HCV population; powerful tool for obtaining more profound insight into the dynamics of variants in the HCV quasispecies | Need for in-depth knowledge to analyze the results | [112,113,195,196] |
PCR: Polymerase chain reaction; HCV: Hepatitis C virus; HBV: Hepatitis B virus; RFLP: Restriction fragment-length polymorphism; RT-PCR: Reverse transcriptase-PCR; qPCR: Quantitative PCR; RFLP: Restriction fragment-length polymorphism; bDNA: Branched DNA technology.